Tango Therapeutics Stock Plunge: A New Offering and Its Impact

Tango Therapeutics stock plunges 15% after announcing a $210 million stock offering and a $15 million PIPE deal. Find out why, despite participation from big names like Farallon Capital and T. Rowe Price, investors reacted negatively to the news, and how this cash infusion could fuel the biotech's cancer treatment research.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.